EVOTEC SE: TRANSLATIONAL BRIDGE beLAB2122 IN COLLABORATION WITH BRISTOL MYERS SQUIBB IDENTIFIES FIRST PROJECT

Hamburg, Germany, 27 October 2021:

  • FIRST PROJECT ORIGINATES FROM THE GERMAN CANCER RESEARCH CENTER (“DKFZ”) AND HEIDELBERG UNIVERSITY IN HEIDELBERG
  • beLAB2122 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. After signing the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic BRIDGE collaboration has now been nominated.

Read more

EVOTEC LAUNCHES “beLAB2122”, TRANSLATING ACADEMIC INNOVATION FROM LEADING GERMAN LIFE SCIENCE REGION IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 13 April 2021:

  • beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY
  • EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ
  • BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Read more